TCGA-43-3394-01A-01R-0980-07
— · cohortSQ2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ2
- subtype
- cohortSQ2
- age_years
- 52
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.450
- E2F_TARGETS+0.390
- OXIDATIVE_PHOSPHORYLATION+0.360
- MTORC1_SIGNALING+0.350
- MYC_TARGETS_V2+0.320
- CHOLESTEROL_HOMEOSTASIS+0.300
- FATTY_ACID_METABOLISM+0.300
- SPERMATOGENESIS+0.270
- G2M_CHECKPOINT+0.260
- DNA_REPAIR+0.250
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.520
- INTERFERON_GAMMA_RESPONSE-0.510
- ALLOGRAFT_REJECTION-0.440
- IL6_JAK_STAT3_SIGNALING-0.420
- COMPLEMENT-0.360
- TNFA_SIGNALING_VIA_NFKB-0.350
- INFLAMMATORY_RESPONSE-0.330
- NOTCH_SIGNALING-0.330
- TGF_BETA_SIGNALING-0.330
- ANGIOGENESIS-0.320
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-BB-8601-01A-11R-2403-07 | — | — | 0.934 |
| 2 | TCGA-33-4582-01A-01R-1443-07 | — | cohortSQ2 | 0.895 |
| 3 | TCGA-33-4532-01A-01R-1201-07 | — | cohortSQ2 | 0.892 |
| 4 | SRR975602 | — | — | 0.882 |
| 5 | TCGA-UF-A71A-06A-11R-A39I-07 | — | — | 0.878 |
| 6 | TCGA-CV-6962-01A-11R-1915-07 | — | — | 0.878 |
| 7 | s0112311 | — | — | 0.877 |
| 8 | TCGA-21-1075-01A-01R-0692-07 | — | cohortSQ2 | 0.876 |
| 9 | TCGA-77-6845-01A-11R-1949-07 | — | cohortSQ2 | 0.875 |
| 10 | C3N-00555 | — | cohortSQ2 | 0.875 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.450 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.390 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.360 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.350 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.320 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.300 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.300 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.270 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.260 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.250 | Idelalisib | — uncovered |
| HYPOXIA | 0.190 | Idelalisib | — uncovered |
| PEROXISOME | 0.190 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.150 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.140 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.080 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.080 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.070 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.050 | Remibrutinib | — uncovered |
| P53_PATHWAY | 0.030 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.030 | Inavolisib | — uncovered |